MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Medpace Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 22, 2026
$619.66+1.19 (+0.19%)
Close on Oct 19, 2026
- Market cap
- $17.69B
- P/E (TTM)
- 36.3
- Dividend yield
- –
Medpace Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metabolic | $747.59M | $651.24M | $587.10M | $467.80M | $362.85M | $297.68M | $256.77M | $189.06M | – | – | 29.5% | +14.8% |
| Other | $744.96M | $457.54M | $376.84M | $244.68M | $159.90M | $126.08M | $138.65M | $124.84M | – | – | 29.4% | +62.8% |
| Oncology | $408.55M | $431.38M | $404.84M | $296.91M | $267.42M | $215.37M | $196.16M | $163.98M | – | – | 16.1% | -5.3% |
| Cardiology | $254.84M | $181.98M | $160.06M | $157.94M | $121.55M | $88.39M | $91.75M | $54.23M | – | – | 10.1% | +40.0% |
| Central Nervous System | $239.37M | $230.45M | $193.69M | $174.63M | $119.69M | $95.15M | $91.26M | $95.21M | – | – | 9.5% | +3.9% |
| AVAI | $134.94M | $156.46M | $163.31M | $118.03M | $110.98M | $103.26M | $86.39M | $77.27M | – | – | 5.3% | -13.8% |
| Direct Service Revenue | – | – | – | – | – | – | $0 | $0 | $386.46M | $370.62M | – | – |
| Reimbursed Out-of-Pocket Revenue | – | – | – | – | – | – | $0 | $0 | $49.69M | $50.96M | – | – |
| Revenue net | – | – | $1.89B | $1.46B | $1.14B | $925.93M | $860.97M | $704.59M | $0 | $0 | – | – |
| Medical Devices | – | – | – | – | – | – | – | $11.77M | – | – | – | – |
| Endocrine | – | – | – | – | – | – | – | $26.00M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Medpace's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.